Targeting Drug Resistance 1: Apoptosis and Autophagy

• 1841 · PDF Venetoclax rewires Notch signaling to drive resistance in North American adult T-cell leukemia/lymphoma Ankit Tanwar, Salman Sadullah Usmani, Sovira Chaudhry, Aditi Shastri, Marina Konopleva, Murali Janakiram, Ali Bazarbachi, B. Hilda Ye, Xingxing Zang, Amit Verma, R. Alejandro Sica
• 1843 · PDF Venetoclax-resistant AML cell models as a platform for exploring new generation drug for BCL2 inhibitor resistance Jinjin Wang, John Liu, Lin Teng
• 1844 · PDF Epigenetic rewiring of BCL6 drives responses and unveils synthetic dependencies in large B cell lymphoma Haopeng Yang, Kevin Bowman, Wenzhi Ji, Sai Gourisankar, Ashley L. Wilson, Zihan Yang, Ethan Marszalek, Stephen M. Hinshaw, Tinghu Zhang, Xiaofan Liu, Andrey Krokhotin, Sabin Nettles, Suprateek Kundu, Gerald R. Crabtree, Nathanael S. Gray, Michael R. Green
• 1845 1845 Targeting mitochondrial and glutathione metabolism sensitizes leukemia cells to DNA-hypomethylating agents and venetoclax combination therapy Pony Yu-Ling Lee, Joy Khag, Marvin A. Aberin, Ta-Yu Liu, Ya-Ting Lu, Kun-Yuan Lin, Chao-Di Chang, Shan-Yun Cheng, Ya-Wen Hung, Chih-Chieh Yang, Yu-Hsien Chang, Chien-Chang Shen, Yao-Ming Chang, Hsing-Chen Tsai, Shih-Yu Chen, Shu-Ping Wang
• 1847 · PDF Improve proteasome inhibitor response by targeting NHE6-mediated endosomal-autophagic machaniery in multiple myeloma Yutong Wang, Liuting Chen, Winston Huang, Jin He, Li Bao, Yihui Fan, Pei Lin, Qing Yi, Jing Yang
• 1848 · PDF IL-1-driven signaling promotes resistance to PI3K and BCL2 inhibitors in B-cell lymphoma preclinical models Alberto J. Arribas, Federica Fuzio, Eleonora Cannas, Michela Chiappa, Luciano Cascione, Giulio Sartori, FIlippo Spriano, Andrea Rinaldi, Georg Stussi, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Andrea Alimonti, Giovanna Damia, Massimo Broggini, Francesco Bertoni
• 1849 · PDF Dual inhibition of AURKA and ERBB overcomes resistance to PI3K/BTK/BCL2 inhibitors in marginal zone lymphoma models Emma Pesenti, Alberto J. Arribas, Maidel Carpio, Eleonora Cannas, Georg Bischof, Francesco Bertoni
• 1850 · PDF Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers Antja-Voy Hartley, Mustafa Al-Dulaimi, Navin R. Mahadevan, Pinar Eser, William W. Feng, Tran Thai, Jeanelle A. Tsai, Caitlyn Weston, Nicholas Tourtillot, Matthew Booker, Joseph Kulesza, Zhaorong Li, Elizabeth Cohen, Sean Lenahan, Choudhury Fabliha Yusuf, Abeba Teshager, Prafulla C. Gokhale, Shweta  Kukreja, Sonsoles Liria Veiga, Rong Li, Xintao Qiu, Henry W. Long, Michael Y. Tolstorukov, Matthew G. Oser, Nathanael S. Gray, David A. Barbie, Pasi A. Janne
• 1851 · PDF Overcoming drug resistance in ccRCC through inhibition of protein phosphatase 5 (PP5) Sarah J. Backe, Rebecca Sager, Jennifer Heritz, John Chisholm, Mark Woodford, Dimitra Bourboulia, Gennady Bratslavsky, Mehdi Mollapour
• 1852 · PDF CRISPR screening identifies BMF loss as a drug-tolerant persister cell survival factor in ALK-rearranged lung cancer Ryohei Katayama, Takahiro Utsumi, Ken Uchibori, Makoto Nishio
• 1853 · PDF NAT10-mediated ac 4 C RNA modification promotes colorectal cancer stemness and 5-FU resistance via ATG5-dependent autophagy Xin Kong, Junyong Weng, Zhe Wang, Ajay Goel
• 1854 · PDF Selective Mcl-1 inhibition with KS18 overcomes apoptotic resistance and enhances FLT3-targeted therapy in acute myeloid leukemia Sahil Jethi, Krishne Gowda, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Manoj K. Pandey
• 1855 · PDF PI3K/mTOR dual inhibitor overcomes ceritinib resistance in ALK-rearranged NSCLC via both apoptosis and autophagy Hyun-Min Ryu, Joo Young Ha, Shinkyo Yoon, Yunkyung Sung, Deokhoon Kim, Chang Hoon Lee, Wanlim Kim, Seyoung Seo, Sang-We Kim, Kang-Seo Park, Dae Ho Lee
• 1856 · PDF Downregulation of ETV4 mediates trametinib resistance via AMPK-ULK1-dependent protective autophagy in breast cancer Xiaodong Liu, Ji Won Kim
• 1857 · PDF Mechanisms of acquired resistance to BTK and BCL2 inhibitors reveal clinically actionable vulnerabilities in B-cell lymphoma Alberto J. Arribas, Camilla Scalise, Eleonora Cannas, Maria Elena Carazzolo, Luciano Cascione, Andrea Rinaldi, Carlo Visco, Davide Rossi, Francesco Bertoni
• 1858 · PDF FAK inhibition by APG-2449 enhances the antitumor activity of MAPK pathway blockade in BRAF V600E-mutant tumor models Zhou Yu, Zhiyan Liang, Xinyi Yao, Shujie He, Dajun Yang, Yifan Zhai
• 1859 1859 Overexpression of fructose transporter increases pro-survival signaling and confers venetoclax resistance in Ph-like B-cell acute lymphoblastic leukemia Serene Xavier, Sonia Rodriguez, Zhaohui Gu, Lucy Ghoda, Stuart Blakemore, Lukas Frenzel, Alexey Danilov, Vinod Pullarkat
• 1860 · PDF Determining mechanisms of ONC212-resistance in uveal melanoma to develop combination therapy strategies Md Alauddin, Chandrani Chattopadhyay
• 1861 · PDF Acquired drug resistance with autophagy is suppressed by fatty acid oxidation inhibition in pancreatic ductal adenocarcinoma Soo-Youl Kim, Sang M. Woo, Wonyoung Choi, Joon Hee Kang, Sung Hoon Sim, Jung Won Chun
• 1862 · PDF Targeting nucleolin overcomes MCL-1-mediated venetoclax resistance in acute myeloid leukemia Kyung Jin Kim, Jihyun Um, Eun Jung Shin, Yu Mi Ji, Sung Hwan Moon, Soo Jin Lee
• 1863 · PDF Development and characterization of the venetoclax-resistant AML model to enable preclinical drug discovery Jifan Yuan, Miaomiao Yu, Gaoxiang Liu, Jian Xiang, Xiangnan Qiang, Zhixiang Zhang
• 1864 · PDF G3BP1 knockdown sensitizes the acute myeloid leukemia cell line HL60 to venetoclax by inducing apoptosis Naoko Hosono, Rie Nishi, Naoko Ida, Chantana Polprasert, Rosesanun Pavaputanont, Takahiro Yamauchi

在会议检索中浏览本分会场